Compare HPF & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPF | OLMA |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 725.5M |
| IPO Year | N/A | 2020 |
| Metric | HPF | OLMA |
|---|---|---|
| Price | $16.07 | $33.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $40.50 |
| AVG Volume (30 Days) | 35.3K | ★ 8.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.99 | $2.86 |
| 52 Week High | $16.80 | $33.50 |
| Indicator | HPF | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 82.93 |
| Support Level | $16.25 | $25.62 |
| Resistance Level | $16.35 | $33.50 |
| Average True Range (ATR) | 0.11 | 2.25 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 3.41 | 96.91 |
John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.